What are the key considerations in managing pregnancy in MPN?

During the European School of Hematology (ESH) 3rd How to Diagnose and Treat: CML/MPN conference, the MPN Hub was pleased to speak to Elisabetta Abruzzese, Sant’Eugenio Hospital, Rome, IT. We asked, What are the key considerations in managing pregnancy in myeloproliferative neoplasms (MPN)?

Elisabetta Abruzzese opens by discussing the increased need for effective treatment strategies for pregnant patients with MPN. Increasing rates of early diagnosis during reproductive years combined with the general trend of later pregnancies both contribute to this need. Abruzzese goes on to outline the risks associated with pregnancy in MPN, including thrombosis and hemorrhage both during and post-partum. The indication for additional therapies to reduce these risks as opposed to discontinuing any current treatment is noted. The interview concludes with a discussion on the appropriate therapeutics for use in essential thrombocytopenia, polycythemia vera, and myelofibrosis.